Tuberculosis Drug Development: Towards a Critical Path for Developing New Regimes to Treat Tuberculosis
Volume 211 suppl 3 June 15, 2015
Click here for access to supplement
Articles:
- Eric Nuermberger and Debra Hanna Assessing the Landscape of Tools and Approaches for Novel Tuberculosis Regimen Development J Infect Dis. (2015) 211 (suppl 3): S81-S82 doi:10.1093/infdis/jiv072
- Tawanda Gumbo, Anne J. Lenaerts, Debra Hanna, Klaus Romero, and Eric Nuermberger Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis J Infect Dis. (2015) 211 (suppl 3): S83-S95 doi:10.1093/infdis/jiv183
- Tawanda Gumbo, Iñigo Angulo-Barturen, and Santiago Ferrer-Bazaga Pharmacokinetic-Pharmacodynamic and Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for Industry and Academia J Infect Dis. (2015) 211 (suppl 3): S96-S106 doi:10.1093/infdis/jiu610
- Vaishali Sahasrabudhe, Tong Zhu, Alfin Vaz, and Susanna Tse Drug Metabolism and Drug Interactions: Potential Application to Antituberculosis Drugs J Infect Dis. (2015) 211 (suppl 3): S107-S114 doi:10.1093/infdis/jiv009
- Helen McIlleron, Susan Abdel-Rahman, Joel Alex Dave, Marc Blockman, and Andrew Owen Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research J Infect Dis. (2015) 211 (suppl 3): S115-S125 doi:10.1093/infdis/jiu600